Melanotan II is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Of his character, he said: "Originally, I was married. I had this kid and I did this research and I didn't know that what I was researching had this effect. And someone got killed and I had these regrets and I'm trying to stop what I'm doing, but they can't let me so they're chasing me. And then all of a sudden I turn into this 24-year-old machinist and I turned to (director) Andrew Davis and I said, 'What happened to the movie I said yes to? What happened to that script? Where did that go?' And he said, 'No, I got something better,' and so I just had to go with it."
The film received mixed reviews from critics, but DiCaprio's performance was praised and earned him the AACTA Award for Best Actor in a Leading Role. Critic Rafer Guzman of Newsday wrote that DiCaprio was not only "tough [...] but also vulnerable, touching, funny, a faker, a human. It's a tremendous, hard-won performance." Matt Zoller Seitz of Roger Ebert's website described his performance as "the movie's greatest and simplest special effect", and "iconic—maybe his career best". The film grossed $353 million worldwide, more than three times its budget. Three films were produced by DiCaprio under Appian Way in 2013—the ensemble crime thriller Runner Runner, which The Guardian's Xan Brooks described as "a lazy, trashy film that barely goes through the motions"; the commercially failed thriller Out of the Furnace; and the black comedy-drama The Wolf of Wall Street. DiCaprio reunited with Scorsese for the fifth time in The Wolf of the Wall Street, a film based on the life of stockbroker Jordan Belfort (played by DiCaprio), who was arrested in the late 1990s for securities fraud and money laundering. DiCaprio wanted to play Belfort ever since he had read his autobiography and won a bidding war with Warner Bros. against Brad Pitt and Paramount Pictures for the rights to Belfort's memoir in 2007. He was fond of Belfort's honest and unapologetic portrayal of his actual experiences in the book, and was inspired by the 2008 financial crisis to make the film. The Wolf of Wall Street received positive reviews for Scorsese's and DiCaprio's work together.
== Z-plasty == This is based upon the principle of mobilizing a full segment of skin from an area to the site needing tissue replacement. The flaps are triangularly shaped opposite each other. It can be used in direct excision and closure of a contracted scar to produce a better looking and healing scar. It helps to elongate and break up a linear scar. It also gives a good result in the release of linear contractures. Z-plasty is of paramount importance to the plastic surgeon and a frequently used method in both single multiple forms.
Sources: en.wikipedia.org
Naja christyi (formerly Boulengerina christyi), commonly known as the Congo water cobra or Christy's water cobra, is a species of venomous snakes belonging to the family Elapidae. The species is native to Sub-Saharan Africa. This species was formerly in the genus Boulengerina, but more recent research by Wallach et al. has shown that Boulengerina is actually a subgenus and Boulengerina christyi is a synonym of Naja christyi. This species has no known subspecies.
=== Project REWARD === The REWARD (Real time wide area radiation surveillance system) project was established to address the threats of nuclear terrorism, missing radioactive sources, radioactive contamination and nuclear accidents. The consortium developed a mobile system for real time wide area radiation monitoring based on the integration of new miniaturized solid state sensors. Two sensors are used: a cadmium zinc telluride (CdZnTe) detector for gamma radiation and a high efficiency neutron detector based on novel silicon technologies. The gamma and neutron detectors are integrated into a single monitoring device called a tag. The sensor unit includes a wireless communication interface to remotely transmit data to a monitoring base station, which also uses a GPS system to calculate the tag's position.
=== Career === In 1966, Kenyon started as an assistant professor of biology at San Francisco State University and became emeritus in 2001. In 1969, Kenyon co-authored Biochemical Predestination with Gary Steinman. Chemist Stephen Berry explained Kenyon's and Steinman's theory as "describing the following causal chain: the properties of the chemical elements dictate the types of monomers that can be formed in prebiotic syntheses, which then dictate the properties of the occurring polymers, which finally dictate the properties of the first eobionts and all succeeding cells." Kenyon's work was about virus production. During the 1969–1970 academic year he was "on a fellowship at the Graduate Theological Union in Berkeley, where he reviewed the contemporary literature on the relationship of science and religion." Then in 1974, he was a visiting scholar to Trinity College, Oxford. Kenyon states that his views changed around 1976 after exposure to the work of young Earth creationists:
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.